PL439032A1 - Peptide constructs for targeted protein degradation - Google Patents

Peptide constructs for targeted protein degradation

Info

Publication number
PL439032A1
PL439032A1 PL439032A PL43903221A PL439032A1 PL 439032 A1 PL439032 A1 PL 439032A1 PL 439032 A PL439032 A PL 439032A PL 43903221 A PL43903221 A PL 43903221A PL 439032 A1 PL439032 A1 PL 439032A1
Authority
PL
Poland
Prior art keywords
peptide
seq
protein degradation
targeted protein
sequence selected
Prior art date
Application number
PL439032A
Other languages
Polish (pl)
Inventor
Maria Górna
Matylda IZERT
Maria KLIMECKA
Patrycja SZYBOWSKA
Anna ANTOSIEWICZ
Piotr TWARDOWSKI
Original Assignee
Uniwersytet Warszawski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Warszawski filed Critical Uniwersytet Warszawski
Priority to PL439032A priority Critical patent/PL439032A1/en
Priority to PCT/IB2022/059128 priority patent/WO2023047376A2/en
Publication of PL439032A1 publication Critical patent/PL439032A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C07K4/04—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Przedmiotem wynalazku jest konstrukt peptydowy zawierający pierwszy peptyd połączony z drugim peptydem, przy czym pierwszy peptyd wiąże pierwsze białko będące celem degradacji, i drugi peptyd wiąże drugie białko, które jest zdolne do inicjacji degradacji pierwszego białka, przy czym pierwszy peptyd ma sekwencję wybraną spośród SEQ ID NO. 1 - 7, a drugi peptyd ma sekwencję wybraną spośród SEQ ID NO. 8 - 12 oraz SEQ ID NO. 28. Wynalazek dotyczy także zastosowania peptydu o sekwencji wybranej spośród SEQ ID NO. 1 - 7 jako kotwicy w degraderach do celowanej degradacji białek i zastosowania peptydu o sekwencji wybranej spośród SEQ ID NO. 8 - 12 albo SEQ ID NO. X jako głowicy w degraderach do celowanej degradacji białek.The invention provides a peptide construct comprising a first peptide linked to a second peptide, wherein the first peptide binds to a first protein to be degraded, and the second peptide binds to a second protein that is capable of initiating degradation of the first protein, wherein the first peptide has a sequence selected from SEQ ID YEAH. 1 - 7 and the second peptide has a sequence selected from SEQ ID NO. 8 - 12 and SEQ ID NO. 28. The invention also relates to the use of a peptide having a sequence selected from SEQ ID NO. 1 - 7 as anchors in degraders for targeted protein degradation and use of a peptide having a sequence selected from SEQ ID NO. 8 - 12 or SEQ ID NO. X as a head in degraders for targeted protein degradation.

PL439032A 2021-09-24 2021-09-24 Peptide constructs for targeted protein degradation PL439032A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL439032A PL439032A1 (en) 2021-09-24 2021-09-24 Peptide constructs for targeted protein degradation
PCT/IB2022/059128 WO2023047376A2 (en) 2021-09-24 2022-09-26 Peptide constructs for targeted protein degradation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL439032A PL439032A1 (en) 2021-09-24 2021-09-24 Peptide constructs for targeted protein degradation

Publications (1)

Publication Number Publication Date
PL439032A1 true PL439032A1 (en) 2023-03-27

Family

ID=84367080

Family Applications (1)

Application Number Title Priority Date Filing Date
PL439032A PL439032A1 (en) 2021-09-24 2021-09-24 Peptide constructs for targeted protein degradation

Country Status (2)

Country Link
PL (1) PL439032A1 (en)
WO (1) WO2023047376A2 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030040043A1 (en) * 2000-07-31 2003-02-27 Steven Haney Characterization of a FtsZ binding site and uses thereof
WO2008054881A2 (en) * 2006-06-07 2008-05-08 The Penn State Research Foundation Antibacterial and plasmid elimination agents
WO2010141468A1 (en) * 2009-06-01 2010-12-09 Way Jeffrey C Methods and molecules for yield improvement involving metabolic engineering
GB201903767D0 (en) * 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
WO2020237066A2 (en) * 2019-05-23 2020-11-26 President And Fellows Of Harvard College Gene editing in diverse bacteria

Also Published As

Publication number Publication date
WO2023047376A2 (en) 2023-03-30
WO2023047376A3 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
ES2571879T3 (en) TNFSF single chain molecules
EA201270517A1 (en) МИКОБАКТЕРИАЛЬНЫЕ ВАКЦИНЫ
PH12022552099A1 (en) Polypeptides, compositions, and their use to treat or limit development of an infection
MX385834B (en) COMPOSITIONS RELATING TO A MUTANT CLOSTRIDIUM DIFFICILE TOXIN AND METHODS THEREOF.
EA200870237A1 (en) SEQUENCE OF PEPTIDES AND COMPOSITIONS
UA107330C2 (en) Tuberculous protein rv3616c and its application
NZ587652A (en) Compositions and methods for the treatment of tumor of hematopoietic origin
WO2010142551A8 (en) Amino acid sequences directed against receptors to cytokines belonging to the il-17 family
AR065289A1 (en) ACTIVINA ANTAGONISTS - ACTRIA AND ITS USES FOR THE PROMOTION OF OSEO GROWTH AND MULTIPLE MYELOMA TREATMENT
CY1113115T1 (en) Peptides - HIV Fusion Inhibitors with Enhanced Biological Properties
CO6190543A2 (en) ANTI-FACTOR ANTIBODIES D HUMANIZED
EA201391548A1 (en) IMMUNOGENIC COMPOSITION
UY28641A1 (en) ANTIBODIES
UA108778C2 (en) ANTI-CANCER Fusion PROTEIN
ZA202304591B (en) Anti-cd73 antibody and use thereof
PL415888A1 (en) Method for producing insulin and its derivatives and the hybrid peptide used in this method
ZA202309516B (en) Anti-ccr8 antibodies
AR067980A1 (en) PEPTIDES OF CDH3 AND AGENTS THAT UNDERSTAND THEM
PH12022552248A1 (en) Anti-human cd19 antibodies
MX2020013732A (en) Methods of manufacturing amino acid compositions.
RU2011154363A (en) COMBINATIONS treasure RRGB PNEUMOCOCCUS
CO6210706A2 (en) UPD-GLUCURONIL TRANSFERASE AND POLYNUCLEOTIDE CODING THE SAME
MX2021000287A (en) Compositions and methods related to engineered fc-antigen binding domain constructs.
ATE495247T1 (en) CHROMOPROTEIN AND FLUOROPROTEINS
BR112017017609A2 (en) fc fusion protein, and pharmaceutical composition.